Loading stock data…
CRDF
$1.71-0.02 (-1.16%)
Market ClosedLast close May 1
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cardiff Oncology, Inc. in the Healthcare sector is trading at $1.71. The stock is currently near its 52-week low of $1.48, remaining 23.0% below its 200-day moving average. Technical signals show neutral RSI of 58 and bullish MACD crossover, explaining why CRDF maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 58) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.71
Potential Upside
5%
Whystock Fair Value$1.80
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treatin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$116.22M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-101.02%
Volume
Today's trading volume
405,281
Recent News
Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar
Cardiff Oncology (NASDAQ:CRDF) interim CEO Mani Mohindru outlined updated clinical results and development plans for the company’s investigational PLK1 inhibitor onvansertib during a webinar focused on first-line RAS-mutated metastatic colorectal cancer (mCRC), a population she described as having s
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC
Cardiff Oncology (NASDAQ:CRDF) used an appearance at Oppenheimer’s 36th Annual Healthcare Conference to highlight updated clinical results and its development plans for onvansertib, an oral, highly selective polo-like kinase 1 (PLK1) inhibitor being studied in RAS-mutated metastatic colorectal cance
Cardiff Oncology: Q4 Earnings Snapshot
SAN DIEGO (AP) — Cardiff Oncology, Inc. CRDF) on Tuesday reported a loss of $7.2 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of 11 cents.
Cardiff Oncology (CRDF) Is Down 43.9% After Advancing Onvansertib And Reshuffling Leadership Team
Cardiff Oncology recently reported positive dose-dependent Phase 2 data for onvansertib in first-line RAS‑mutated metastatic colorectal cancer and outlined plans to move the 30 mg dose into a registrational trial, while simultaneously announcing a leadership reshuffle including a new interim CEO and the departure of its CFO as of January 27, 2026. The combination of advancing onvansertib toward potential late-stage development and installing an experienced biotech operator as interim CEO...
Cardiff Oncology Taps Interim CEO, Picks 30mg Onvansertib Regimen for 2026 Registrational mCRC Study
Cardiff Oncology (NASDAQ:CRDF) outlined a management transition and provided an updated clinical data readout for onvansertib during a company conference call focused on its ongoing Phase II CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer (mCRC). Leadership transition framed a